Zentralbl Chir 2013; 138(S 01): S32-S39
DOI: 10.1055/s-0033-1350870
Übersicht
Georg Thieme Verlag KG Stuttgart · New York

Die transpulmonalarterielle Chemoembolisation – vom Labor zur klinischen Anwendung

Pulmonary Artery Chemoembolization – From Bench to Bedside
P. Schneider
Klinik für Chirurgie und Thoraxchirurgie, DRK Kliniken Berlin | Mitte, Deutschland
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
22. Oktober 2013 (online)

Zusammenfassung

Die lokoregionären Ansätze bei inoperablen Lungenmetastasen finden in der Literatur wenig Beachtung. Es liegen zwar ausführliche tierexperimentelle Untersuchungen über Wirksamkeit und fehlende Toxizität der isolierten Lungenperfusion (ILP) vor, allerdings sind klinische Studien begrenzt. Dies liegt wahrscheinlich an der Invasivität und am großen technischen Aufwand der Therapie und dies meist in der palliativen Situation. Erst seit Kurzem wird die Chemoembolisation der Lunge im Tiermodell durchgeführt und mit der isolierten Lungenperfusion und der intravenösen Therapie verglichen. Mit simultaner einseitiger Injektion degradierbarer Stärkemikrosphären und Carboplatin in die Pulmonalarterie wurde eine temporäre reversible Embolisation auf kapillärer und arteriolärer Ebene erreicht. Die Chemoembolisation war der intravenösen Chemotherapie überlegen und zeigte ein ähnliches Ansprechen wie die isolierte Lungenperfusion im solitären Lungenmetastasenmodell. Sie war nicht mit einer Frühtoxizität behaftet, und die Spätauswirkung auf das Lungenparenchym war mit denen der intravenösen Therapie und der isolierten Lungenperfusion vergleichbar. Bei der Chemoembolisation wird nur ein Drittel der üblichen, intravenös verabreichten Zytostatikadosis verwendet, daher sind die allgemeinen Nebenwirkungen nicht limitierend. Im Vergleich zur intravenösen Therapie wurde eine signifikant höhere Zytostatikakonzentration im Tumorgewebe, in den Lymphknoten und im gesunden Lungengewebe erreicht. Im Großtiermodell konnte gezeigt werden, dass diese neue Methode interventionell über einen Pulmonaliskatheter durchführbar ist und nicht zu einer relevanten Veränderung des Kreislaufs führt. Chronische Schäden nach 6 Monaten sind nicht aufgetreten. Erste klinische Anwendungen zeigen demnach die Machbarkeit und die gute Toleranz bei Patienten mit inoperablen Lungenmetastasen.

Abstract

Locoregional approaches for inoperable lung metastases described in the literature are limited to isolated lung perfusion (ILP). A lot of experimental studies show feasibility and good oncological response with low toxicity. However, clinical applications are rare – probably due to the invasiveness of the procedure in a palliative aim. Recently chemoembolisation of the lung in a small-animal model was performed and compared to isolated lung perfusion and intravenous therapy. Using a simultaneous unilateral injection of degradable starch microspheres and carboplatin into the pulmonary artery, temporary reversible embolization at the capillary and arteriolar level has been achieved. Chemoembolization was superior to intravenous chemotherapy and had a response comparable to that of isolated lung perfusion in the solitary lung metastasis model. It was not associated with early toxicity and the long-term effect on lung parenchyma was similar to those of intravenous therapy and isolated lung perfusion. Since only a third of the normal intravenous cytostatic dose is used in chemoembolization, the general side effects are thus not a limiting factor. In the large-animal model, the new method can be performed interventionally via a pulmonary catheter without changing the circulation relevantly. After 6 months no chronic injury was seen. First clinical applications show that the procedure was well tolerated in patients with unresectable metastases.

 
  • Literatur

  • 1 Klopp CT, Alford TC, Bateman J et al. Fractionated intra-arterial cancer chemotherapy with methyl bis-amine hydrochloride. Ann Surg 1950; 132: 811-832
  • 2 Eggermont AM, Schraffordt Koops H, Klausner JM et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 1996; 224: 756-764 discussion 764–765
  • 3 Lienard D, Ewalenko P, Delmotte JJ et al. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992; 10: 52-60
  • 4 Creech Jr O, Krementz ET, Ryan RF et al. Chemotherapy of cancer: Regional Perfusion utilizing an extracorporeal circuit. Ann Surg 1958; 148: 616-632
  • 5 Jacobs JK, Flexner JM, Scott HW. Selective isolated perfusion of the right or left lung. J Thoracic and Cardiovsac Surg 1961; 42: 546-552
  • 6 Pierpont H, Blades B. Lung perfusion with chemotherapeutic agents. J Thoracic and Cardiovsc Surg 1960; 39: 159-165
  • 7 Weksler B, Schneider A, Ng B et al. Isolated single lung perfusion in the rat: an experimental model. J Appl Physiol 1993; 74: 2736-2739
  • 8 Hendriks JM, Van Schil PE, Van Oosterom AA et al. Isolated lung perfusion with melphalan prolongs survival in a rat model of metastatic pulmonary adenocarcinoma. Eur Surg Res 1999; 31: 267-271
  • 9 Burt ME, Liu D, Abolhoda A et al. Isolated lung perfusion for patients with unresectable metastases from sarcoma: a phase I trial. Ann Thor Surg 2000; 69: 1542-1549
  • 10 Johnston MR, Minchin R, Dawson CA. Lung perfusion with chemotherapy in patients with unresectable metastatic sarcoma to the lung or diffuse bronchioloalveolar carcinoma. J Thorac Cardiovasc Surg 1995; 110: 368-373
  • 11 Pass HI, Mew DJ, Kranda KC et al. Isolated lung perfusion with tumor necrosis factor for pulmonary metastases. Ann Thorac Surg 1996; 61: 1609-1617
  • 12 Ratto GB, Toma S, Civalleri D et al. Isolated lung perfusion with platinum in the treatment of pulmonary metastases from soft tissue sarcomas. J Thorac Cardiovasc Surg 1996; 112: 614-622
  • 13 Schröder C, Fisher S, Pieck AC et al. Technique and results of hyperthermic (41 degrees C) isolated lung perfusion with high-doses of cisplatin for the treatment of surgically relapsing or unresectable lung sarcoma metastasis. Eur J Cardiothorac Surg 2002; 22: 41-46
  • 14 Hendriks JM, Grootenboers MJ, Schramel FM et al. Isolated lung perfusion with melphalan for resectable lung metastases: a phase I clinical trial. Ann Thorac Surg 2004; 78: 1919-1926 discussion 1926–1927
  • 15 Karakousis CP, Park HC, Sharma SD et al. Regional chemotherapy via the pulmonary artery for pulmonary metastases. J Surg Oncol 1981; 18: 249-255
  • 16 Furrer M, Lardinois D, Thormann W et al. Cytostatic lung perfusion by use of an endovascular blood flow occlusion technique. Ann Thorac Surg 1998; 65: 1523-1528
  • 17 Young AE. Therapeutic embolisation. Br Med J (Clin Res Ed) 1981; 283: 1144-1145
  • 18 Pauser S, Wagner S, Lippmann M et al. Evaluation of efficient chemoembolization mixtures by magnetic resonance imaging therapy monitoring: an experimental study on the VX2 tumor in the rabbit liver. Cancer Res 1996; 56: 1863-1867
  • 19 Pohlen U, Berger G, Binnenhei M et al. Increased carboplatin concentration in liver tumors through temporary flow retardation with starch microspheres (Spherex) and gelatin powder (Gelfoam): an experimental study in liver tumor-bearing rabbits. J Surg Res 2000; 92: 165-170
  • 20 Taguchi T, Ogawa N, Bunke B. The use of degradable starch microspheres (Spherex) with intra-arterial chemotherapy for the treatment of primary and secondary liver tumors – Results of a phase III clinical trial. Reg Cancer Treat 1992; 4: 161-165
  • 21 Wu KT, Wang CC, Lu LG. Hepatocellular carcinoma: Clinical study of long-term survival and choice of treatment modalities. World J Gastroenterol 2013; 19: 3649-3657
  • 22 Lindberg B, Lote K, Teder H. Biodegradable Starch Microspheres – a new medical Tool. In: Davis SS, Illum L, McVie JG, Tomlinson E, eds. Microspheres and Drug Therapy. Amsterdam: Elsevier; 1984: 153-188
  • 23 Schneider P, Foitzik T, Kahrau S et al. An experimental rat model for studying pulmonary microcirculation by in vivo videomicroscopy. Microvasc Res 2001; 62: 421-434
  • 24 Schneider P. Chemoembolization of the Lung. In: van Schill P, ed. Lung Metastases and isolated Lung Perfusion. New York: Nova Science Publisher Inc; 2007: 151-164
  • 25 Schneider P, Foitzik T, Pohlen U et al. Temporary unilateral microembolization of the lung – a new approach to regional chemotherapy for pulmonary metastases. J Surg Res (107) 159-166
  • 26 Schneider P, Kampfer S, Loddenkemper C et al. Chemoembolization of the lung improves tumor control in a rat model. Clin Cancer Res 2002; 8: 2463-2468
  • 27 Pohlen U, Rieger H, Meyer BT et al. Chemoembolization of lung metastases–pharmacokinetic behaviour of carboplatin in a rat model. Anticancer Res 2007; 27: 809-815
  • 28 Pohlen U, Rieger H, Albrecht T et al. Chemoembolization with carboplatin of the lung. Feasibility and toxicity in a pig model. Anticancer Res 2007; 27: 1503-1508
  • 29 Pfannschmidt J, Hoffmann H, Dienemann H. Reported outcome factors for pulmonary resection in metastatic colorectal cancer. J Thorac Oncol 2010; 5 (Suppl. 02) S172-S178
  • 30 Vogl TJ, Naguib NN, Gruber-Rouh T et al. Microwave ablation therapy: clinical utility in treatment of pulmonary metastases. Radiology 2011; 261: 643-651 Erratum in: Radiology 2013; 266: 1000 Erratum in: Radiology 2013; 266: 1000
  • 31 Gadaleta CD, Solbiati L, Mattioli V et al. Unresectable lung malignancy: combination therapy with segmental pulmonary arterial chemoembolization with drug-eluting microspheres and radiofrequency ablation in 17 patients. Radiology 2013; 267: 627-637
  • 32 Vogl TJ, Wetter A, Lindemayr S et al. Treatment of unresectable lung metastases with transpulmonary chemoembolization: preliminary experience. Radiology 2005; 234: 917-922
  • 33 Vogl TJ, Herzog C, Zangos S et al. [Palliative treatment of primary lung tumors with transpulmonary chemoembolization (TPCE)]. Rofo 2007; 179: 300-307
  • 34 Vogl TJ, Lehnert T, Zangos S et al. Transpulmonary chemoembolization (TPCE) as a treatment for unresectable lung metastases. Eur Radiol 2008; 18: 2449-2455
  • 35 Balduyck B, Van Thielen J, Cogen A et al. Quality of life evolution after pulmonary metastasectomy: a prospective study comparing isolated lung perfusion with standard metastasectomy. J Thorac Oncol 2012; 7: 1567-1673
  • 36 Miller BJ, Rosenbaum AS. The vascular supply to metastatic tumors of the lung. Surg Gynecol Obstet 1967; 125: 1009-1012
  • 37 Milne EN, Noonan CD, Margulis AR et al. Vascular supply of pulmonary metastases. Experimental study in rats. Invest Radiol 1969; 4: 215-229
  • 38 Hagenaars M, Ensink NG, Basse PH et al. The microscopic anatomy of experimental rat CC531 colon tumour metastases: consequences for immunotherapy?. Clin Exp Metastasis 2000; 18: 189-196
  • 39 Cornalba GP, Vella A, Barbosa F et al. Bronchial and nonbronchial systemic artery embolization in managing haemoptysis: 31 years of experience. Radiol Med 2012; Aug 8 [Epub ahead of print]